Celltrion, Inc.
068270 · Korea Exchange (KRX) — KOSPI · Healthcare — Biotechnology (Biosimilars)
Tentang perusahaan
Celltrion is South Korea's leading biotechnology company and a global pioneer in biosimilar drug development and manufacturing, producing biosimilars of infliximab (Remsima), trastuzumab (Herzuma), rituximab (Truxima), and other biologics. The company merged with Celltrion Healthcare in 2023 to create a fully integrated biopharmaceutical company spanning discovery to commercialization. Celltrion's biosimilar portfolio is marketed in over 100 countries.
| Bursa | Korea Exchange (KRX) — KOSPI |
| Kode saham | 068270 |
| Sektor | Healthcare — Biotechnology (Biosimilars) |
| Kapitalisasi pasar indikatif USD | $25.00B |
| Situs web | Kunjungi situs web |
Harga langsung
Memuat harga terkini…
| Kapitalisasi pasar | |
| Kisaran harian | |
| Kisaran 52 minggu |
Cara membeli
Di pasar asal (Korea Exchange (KRX) — KOSPI), dapat diakses melalui broker global yang menawarkan bursa tersebut:
- Interactive Brokers — Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank — Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) — Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading — International stock trading on a number of developed and emerging markets.
- Korea Exchange — pencatatan resmi di bursa
Hanya informasi ketersediaan — bukan rekomendasi atau penawaran untuk membeli. Konfirmasikan kelayakan, biaya, dan ketersediaan terkini dengan broker Anda.
Perusahaan lain di South Korea
Data perusahaan dan harga langsung apa pun bersifat indikatif, mungkin tertunda atau tidak akurat, dan hanya untuk riset — bukan saran investasi. Verifikasi dengan bursa, pengajuan perusahaan, dan broker Anda.